Nodify XL2® testing helps identify patients with likely benign lung nodules and supports clinical decision-making so physicians can more confidently identify patients who have a reduced risk of malignancy and may avoid unnecessary invasive procedures.
Learn more about:
The Nodify XL2 test is intended for patients with incidental lung nodules:
The Nodify Lung Blood Specimen Collection Kit is used for both the Nodify CDT and the Nodify XL2 proteomic tests.
DOWNLOAD OUR INFORMATIONAL BROCHURE
ORDER NODIFY LUNG TESTING
CONTACT OUR TEAM
1. Swensen SJ, Silverstein MD, Ilstrup DM, et. al. "The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules." Arch Intern Med. 1997 Apr 28; 157(8):849-55.
2. Silvestri G et al. "Assessment of plasma proteomics biomarkers ability to distinguish benign from malignant lung nodules." CHEST. 2018 Sept. 154(3):491-500.
A leading data-driven diagnostic solutions company helping answer critical clinical questions faced by physicians, researchers, and biopharmaceutical companies, with a primary focus in lung disease.
CORPORATE HEADQUARTERS
2970 Wilderness Place, Suite 100
Boulder, CO 80301
Phone (866) 432-5930
Fax (866) 432-3338
© Copyright 2020 Biodesix.
All Rights Reserved.